Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Jula Inrig Sells 4,207 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 4,207 shares of Travere Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total value of $84,644.84. Following the sale, the insider now directly owns 85,236 shares in the company, valued at $1,714,948.32. This trade represents a 4.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.76, for a total transaction of $8,254.40.
• On Friday, January 3rd, Jula Inrig sold 2,066 shares of Travere Therapeutics stock. The stock was sold at an average price of $19.10, for a total transaction of $39,460.60.

Travere Therapeutics Trading Up 4.4 %

Travere Therapeutics stock opened at $21.10 on Wednesday. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $21.56. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The firm has a 50-day moving average price of $18.69 and a 200-day moving average price of $15.47.

Analyst Upgrades and Downgrades

Several research analysts have commented on TVTX shares. Scotiabank increased their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Piper Sandler boosted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Barclays raised their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Guggenheim increased their target price on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Finally, HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Trading of Travere Therapeutics

Several institutional investors have recently added to or reduced their stakes in TVTX. Emerald Advisers LLC grew its stake in shares of Travere Therapeutics by 19.8% during the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock valued at $27,430,000 after buying an additional 323,513 shares during the last quarter. Finepoint Capital LP boosted its holdings in Travere Therapeutics by 0.3% during the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock valued at $24,934,000 after acquiring an additional 5,539 shares during the period. Geode Capital Management LLC grew its position in Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in Travere Therapeutics by 26.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after purchasing an additional 244,444 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Travere Therapeutics by 12.0% during the third quarter. Parkman Healthcare Partners LLC now owns 1,086,067 shares of the company’s stock worth $15,194,000 after purchasing an additional 116,175 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.